Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis
Patients who undergo surgery to treat BPH may desire to discontinue or bypass BPH medications. However, these data demonstrated that approximately 10% of BPH patients used medication through five years postoperatively, regardless of which procedure they underwent.
Authors
- Bilal Chughtai (ORCID: https://orcid.org/0000-0002-0515-2578)
- Claus G. Roehrborn (ORCID: https://orcid.org/0000-0003-4024-7369)
- Steven A. Kaplan (ORCID: https://orcid.org/0000-0003-2558-7306)
- Dean Elterman (ORCID: https://orcid.org/0000-0003-1507-7783)
- Ronald P. Kaufman
Institutions
- Northwell Health (US)
- University of Toronto (CA)
- Southwestern Medical Center (US)
- Syosset Hospital (US)
- Albany Medical Center Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1038/s41391-025-00953-0
- Citations
- 3
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 5.51